➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Express Scripts
McKesson
Johnson and Johnson
Harvard Business School

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,049,328


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,049,328 protect, and when does it expire?

Patent 7,049,328 protects FERRIPROX and is included in two NDAs.

This patent has eighteen patent family members in fifteen countries.

Summary for Patent: 7,049,328
Title:Use for deferiprone
Abstract: A method of treating iron induced cardiac disease in a patient with iron overload, such as in thalassemia or the like comprising administering to the patient a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
Inventor(s): Spino; Michael (Pickering, CA), Piga; Antonio (Moncalieri, IT)
Assignee: Apotex Inc. (Weston, CA)
Application Number:10/311,814
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,049,328
Patent Claim Types:
see list of patent claims
Use; Delivery; Composition; Dosage form; Formulation;

Recent additions to Drugs Protected by US Patent 7,049,328

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Chiesi FERRIPROX deferiprone TABLET 212269 May 19, 2020 RX Yes   Start Trial   Start Trial U-735 METHOD OF TREATING CHRONIC IRON OVERLOAD
Chiesi FERRIPROX deferiprone TABLET 021825 Jul 25, 2019 RX Yes   Start Trial   Start Trial U-735 METHOD OF TREATING CHRONIC IRON OVERLOAD
Chiesi FERRIPROX deferiprone TABLET 021825 Oct 14, 2011 RX Yes   Start Trial   Start Trial U-735 METHOD OF TREATING CHRONIC IRON OVERLOAD
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 7,049,328

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-002 Apr 20, 2018 RX Yes No   Start Trial   Start Trial METHOD OF TREATING CHRONIC IRON OVERLOAD   Start Trial
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-001 Sep 9, 2015 RX Yes Yes   Start Trial   Start Trial METHOD OF TREATING CHRONIC IRON OVERLOAD   Start Trial
Chiesi FERRIPROX deferiprone TABLET;ORAL 021825-002 Jul 25, 2019 RX Yes No   Start Trial   Start Trial METHOD OF TREATING CHRONIC IRON OVERLOAD   Start Trial
Chiesi FERRIPROX deferiprone TABLET;ORAL 021825-001 Oct 14, 2011 RX Yes Yes   Start Trial   Start Trial METHOD OF TREATING CHRONIC IRON OVERLOAD   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,049,328

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Canada2313270Jun 30, 2000
PCT Information
PCT FiledJune 28, 2001PCT Application Number:PCT/CA01/00956
PCT Publication Date:January 10, 2002PCT Publication Number: WO02/02114

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
McKinsey
Harvard Business School
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.